Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  JAMA Oncology

• Publication date

  2016-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamaoncol.2016.0405PMID 27100819
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

  2016cited by this paper
• Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma.

  2014cited by this paper
• PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

  2014cited by this paper
• Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.

  2014cited by this paper
• Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs

  2014cited by this paper
• In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C

  2014cited by this paper
• MEK inhibition in non-small cell lung cancer.

  2014cited by this paper
• Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

  2014cited by this paper
• Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

  2014cited by this paper
• RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.

  2014cited by this paper
• KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy

  2013cited by this paper
• Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

  2013cited by this paper
• Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.

  2013cited by this paper
• Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer

  2013cited by this paper
• Comparison of the characteristics and clinical course of 677 patients with metastatic lung cancers with mutations in KRAS codons 12 and 13.

  2013cited by this paper
• K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

  2013cited by this paper
• Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.

  2013cited by this paper
• Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

  2013cited by this paper
• Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.

  2013cited by this paper
• The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.

  2012cited by this paper
• Twist1 Suppresses Senescence Programs and Thereby Accelerates and Maintains Mutant Kras-Induced Lung Tumorigenesis

  2012cited by this paper
• Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

  2012cited by this paper
• EZH2 couples pancreatic regeneration to neoplastic progression.

  2012cited by this paper
• C-Raf is required for the initiation of lung cancer by K-Ras(G12D).

  2011cited by this paper
• mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients

  2011cited by this paper
• Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.

  2011cited by this paper
• A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

  2011cited by this paper
• Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.

  2010cited by this paper
• A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

  2010cited by this paper
• Siah proteins: novel drug targets in the Ras and hypoxia pathways.

  2009cited by this paper
• Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

  2009cited by this paper
• KRAS mutations in non-small cell lung cancer.

  2009cited by this paper
• A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.

  2009cited by this paper
• Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.

  2009cited by this paper
• Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from German Centers in the TRUST Study

  2008cited by this paper
• Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

  2008cited by this paper
• Ras oncogenes: split personalities

  2008cited by this paper
• Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers

  2008cited by this paper
• Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth.

  2008cited by this paper
• Report TORC1 Is Essential for NF1-Associated Malignancies

  2008cited by this paper
• Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

  2008cited by this paper
• Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation.

  2007cited by this paper
• The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer

  2007cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

  2005cited by this paper
• The Concept of Synthetic Lethality in the Context of Anticancer Therapy

  2005cited by this paper
• Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

  2004cited by this paper
• High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase Inhibitors*

  2003cited by this paper
• Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.

  2002cited by this paper
• Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.

  2001cited by this paper
• Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma.

  2000cited by this paper
• Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase g

  2000cited by this paper
• LUCA15, a putative tumour suppressor gene encoding an RNA‐binding nuclear protein, is down‐regulated in ras‐transformed Rat‐1 cells

  2000cited by this paper
• Increasing Complexity of the Ras Signaling Pathway*

  1998cited by this paper
• Increasing complexity of Ras signaling

  1998cited by this paper
• Ras recruits Raf‐1 to the plasma membrane for activation by tyrosine phosphorylation.

  1995cited by this paper
• Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane

  1994cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper

• Discovery of KRAS-G12D degraders via exploration of various E3 ligases.

  2026cites this paper
• ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer.

  2025cites this paper
• Comprehensive analysis of oncogenic determinants across tumor types via multi-omics integration.

  2025cites this paper
• Targeting ATP7A-Dependent Copper Metabolic Homeostasis Induces Cuproptosis and Suppresses the Progression of Mutant KRAS-Driven Lung Cancer.

  2025cites this paper
• Shaping the battlefield: EGFR and KRAS tumor mutations’ role on the immune microenvironment and immunotherapy responses in lung cancer

  2025cites this paper
• Molecular drivers in CNS metastatic disease.

  2025cites this paper
• CASTOR1: A Novel Tumor Suppressor Linking mTORC1 and KRAS Pathways in Tumorigenesis and Resistance to KRAS-Targeted Therapies in Non-Small Cell Lung Cancer

  2025cites this paper
• Differential Response and Resistance to KRAS‐Targeted Therapy

  2025cites this paper
• Prospective Upfront Next-Generation Sequencing for Advanced Non-Small Cell Lung Cancer: Real-World Outcomes from the Ion Chiricuță Oncology Institute

  2025cites this paper
• KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy

  2025cites this paper
• KRAS4B oncogenic mutants promote non-small cell lung cancer progression via the interaction of deubiquitinase USP25 with RNF31.

  2025cites this paper
• Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy

  2025cites this paper
• AI cancer driver mutation predictions are valid in real-world data

  2025cites this paper
• Optimizing Therapeutic Approaches for Aggressive Molecular Subtypes of Metastatic NSCLC.

  2025cites this paper
• Machine learning predictions improve identification of real-world cancer driver mutations

  2024cites this paper
• Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.

  2024cites this paper
• The Association Between Modified Albumin-Bilirubin (mALBI) and Survival in Advanced Non-small Cell Lung Cancer Patients Treated With Immunotherapy

  2024cites this paper
• Oncogenic alterations in advanced NSCLC: a molecular super-highway

  2024cites this paper
• Immunotherapy in Non-Small-Cell Lung Cancer: A Modified Delphi Survey Consensus on First Line Treatment, Special Populations and Rechallenge

  2024cites this paper
• Sequence-defined phosphoestamers for selective inhibition of the KRASG12D/RAF1 interaction

  2024cites this paper
• Blockade of purine metabolism reverses macrophage immunosuppression and enhances anti-tumor immunity in non-small cell lung cancer.

  2024cites this paper
• HDAC10 inhibits non-small-cell lung cancer cell ferroptosis through the microRNA-223-5p-SLC7A11 axis.

  2024cites this paper
• Development of a Practical Telescoped Process to Prepare (P)-7-(2-Amino-6-fluorophenyl)-4-hydroxy-6-(trifluoromethyl)pyrido[3,4-d]pyrimidin-8(7H)-one: a Key Intermediate of KRASG12C Inhibitor GH35

  2024cites this paper
• Immune status and combined immunotherapy progression in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant tumors.

  2024cites this paper
• Photonanozyme–Kras–ribosome combination treatment of non-small cell lung cancer after COVID-19

  2024cites this paper
• Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs

  2024cites this paper
• Nomogram model for the diagnosis of solitary nodular pulmonary mucinous adenocarcinoma

  2024cites this paper
• Analysis of the interlink between glucose-6-phosphate dehydrogenase (G6PD) and lung cancer through multi-omics databases

  2024cites this paper
• Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy

  2024cites this paper
• Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysis

  2024cites this paper
• Immunotherapy: an emerging modality to checkmate brain metastasis

  2023cites this paper
• Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancer

  2023cites this paper
• First-line immunotherapy in non-small cell lung cancer: how to select and where to go

  2023cites this paper
• Cellular Senescence in Non-Small Cell Lung Cancer.

  2023cites this paper
• A New Dawn for Targeted Cancer Therapy: Small Molecule Covalent Binding Inhibitor Targeting K-Ras (G12C).

  2023cites this paper
• Clinical outcomes of KRAS-mutant non-small cell lung cancer under untargeted therapeutic regimes in the real world: a retrospective observational study

  2023cites this paper
• An in vitro-transcribed circular RNA targets the mitochondrial inner membrane cardiolipin to ablate EIF4G2+/PTBP1+ pan-adenocarcinoma

  2023cites this paper
• Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics

  2023cites this paper
• Pharmacological Ascorbate Elicits Anti-Cancer Activities against Non-Small Cell Lung Cancer through Hydrogen-Peroxide-Induced-DNA-Damage

  2023cites this paper
• A Chamber-Based Digital PCR Based on a Microfluidic Chip for the Absolute Quantification and Analysis of KRAS Mutation

  2023cites this paper
• Clinical characteristics analysis and prognostic nomogram for predicting survival in patients with second primary prostate cancer: a population study based on SEER database

  2023cites this paper
• RNF128 expression in lung adenocarcinoma is a favorable prognostic factor associated with decreased tumor‐associated macrophages

  2023cites this paper
• Prediction of KRASG12C inhibitors using conjoint fingerprint and machine learning-based QSAR models.

  2023cites this paper
• Recent progress of biosensors for the detection of lung cancer markers.

  2023cites this paper
• Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

  2023cites this paper
• Genetic differences between smokers and never-smokers with lung cancer

  2023cites this paper
• Syntenin-1-mediated small extracellular vesicles promotes cell growth, migration, and angiogenesis by increasing onco-miRNAs secretion in lung cancer cells

  2022cites this paper
• Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk

  2022cites this paper
• KRAS in NSCLC: State of the Art and Future Perspectives

  2022cites this paper
• Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)

  2022influential citation
• Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

  2022cites this paper
• The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials

  2022cites this paper
• Novel natural inhibitors targeting KRAS G12C by computational study

  2022cites this paper
• KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer

  2022cites this paper
• Risk of colon cancer-related death in people who had cancer in the past

  2022cites this paper
• Colorectal cancer-derived exosomes and modulation KRAS signaling

  2022cites this paper
• Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives

  2022cites this paper
• Identification of TRP-Related Subtypes, Development of a Prognostic Model, and Characterization of Tumor Microenvironment Infiltration in Lung Adenocarcinoma

  2022cites this paper
• A whole-slide image (WSI)-based immunohistochemical feature prediction system improves the subtyping of lung cancer.

  2022cites this paper
• CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma

  2022cites this paper
• Intrinsically disordered proteins: Ensembles at the limits of Anfinsen's dogma.

  2022cites this paper
• Second primary malignancies in oral tongue cancer: A Surveillance, Epidemiology, and End Result–based analysis evaluating the basic characteristics, survival outcomes, and predictive factors

  2022cites this paper
• Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies

  2022cites this paper
• Circ_0020123 enhances the cisplatin resistance in non-small cell lung cancer cells partly by sponging miR-140-3p to regulate homeobox B5 (HOXB5)

  2022cites this paper
• The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations.

  2021cites this paper
• The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)

  2021cites this paper
• LSD1-mediated stabilization of SEPT6 protein activates the TGF-β1 pathway and regulates non-small-cell lung cancer metastasis

  2021cites this paper
• Survival outcomes in prostate cancer patients with a prior cancer

  2021cites this paper
• KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma

  2021cites this paper
• Unique Profile of Driver Gene Mutations in Patients With Non-Small-Cell Lung Cancer in Qujing City, Yunnan Province, Southwest China

  2021cites this paper
• First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

  2021influential citation
• Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma

  2021cites this paper
• Potential therapeutic uses of rexinoids.

  2021cites this paper
• Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer

  2021cites this paper
• GRAIL inhibits the growth, migration and invasion of lung adenocarcinoma cells by modulating STAT3/C-MYC signaling pathways.

  2021cites this paper
• Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases

  2021cites this paper
• Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas

  2021cites this paper
• The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer

  2021cites this paper
• Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer

  2021cites this paper
• KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond.

  2021cites this paper
• A method establishment and comparison of in vivo lung cancer model development platforms for evaluation of tumour metabolism and pharmaceutical efficacy.

  2021cites this paper
• KRAS mutation: from undruggable to druggable in cancer

  2021cites this paper
• Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR

  2021cites this paper
• The incidence and predictors of new brain metastases in patients with non-small cell lung cancer following discontinuation of systemic therapy.

  2021cites this paper
• The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients

  2021influential citation
• Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer

  2021cites this paper
• KRAS K104 modification affects the KRASG12D-GEF interaction and mediates cell growth and motility

  2020cites this paper
• DDDT_A_228123 1583..1592

  2020cites this paper
• OTT_A_272553 10453..10464

  2020cites this paper
• Systemic Therapy of Brain Metastases: Lung Cancer

  2020cites this paper
• Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival

  2020cites this paper
• Gallic Acid Impedes Non-Small Cell Lung Cancer Progression via Suppression of EGFR-Dependent CARM1-PELP1 Complex

  2020cites this paper
• Downregulation of SETBP1 promoted non-small cell lung cancer progression by inducing cellular EMT and disordered immune status.

  2020cites this paper
• FGF/FGFR signaling pathway involved resistance in various cancer types

  2020cites this paper
• Long non-coding RNA NCK1-AS1 promotes the proliferation, migration and invasion of non-small cell lung cancer cells by acting as a ceRNA of miR-137.

  2020cites this paper
• Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs.

  2020cites this paper
• Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

  2020influential citation
• Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma.

  2020cites this paper
• Immunotherapy in oncogene addicted non-small cell lung cancer

  2020cites this paper
• The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.

  2020cites this paper